Literature DB >> 24133311

Effects of montelukast sodium on tendon healing: An experimental study.

Atilla Polat1, Mehmet Kerem Canbora, Dilek Akakin, Faruk Aykanat.   

Abstract

INTRODUCTION: Montelukast sodium (MS) a selective leukotriene antagonist of the cysteinyl leukotriene receptor, has been used in the treatment of asthma and allergic rhinitis. In this study, we evaluated the effect of MS on the early inflammatory phase (histological) of nonsynovial tendon healing.
MATERIALS AND METHODS: Rats were divided randomly into two groups (n = 6 each). MS (Singulair) was administered to one group at 10 mg/kg/day [250 g/day intraperitoneally (i.p.)]. The control group was administered 250 g/day of 0.9% saline i.p. This nonsynovial tendon was longitudinally divided at the midportion, cut transversely and then sutured. In both groups, the rats were sacrificed by decapitation 10 days later.
RESULTS: Decreased inflammatory cell infiltration and more properly oriented collagen fibres were observed in the MS group's histopathological specimens as compared to the control group's (P < 0.05). Additionally, vascularity was decreased in the MS group.
CONCLUSION: MS decreased tendon healing, apparently by inhibiting the early inflammatory phase of nonsynovial tendon healing.

Entities:  

Keywords:  Achilles tendon; montelukast; rats; tendon

Year:  2013        PMID: 24133311      PMCID: PMC3796924          DOI: 10.4103/0019-5413.118207

Source DB:  PubMed          Journal:  Indian J Orthop        ISSN: 0019-5413            Impact factor:   1.251


INTRODUCTION

Montelukast sodium (MS) is a potent, selective antagonist of the cysteinyl leukotriene (CysLT1) receptor and is under investigation for the treatment of bronchial asthma and allergic rhinitis, which are chronic inflammatory disease that affect people worldwide. MS is the drug used for longer periods or lifelong. Their healing effects on patients with tendon injury and fractures have been investigated by many authors. In this study, we investigated the effect of MS on the acute inflammatory phase of tendon healing in injured tendon. The three main stages of tendon healing are inflammation, repair or proliferation and remodeling. We focused on the inflammatory phase of tendon healing because MS is thought to affect only this phase, which lasts appproximately 10 days.1234 Some drugs have negative effects on tendon healing, particularly (NSAIDs).5 In clinical practice; the treatment of common nonsynovial tendon injuries and asthmatic patients with NSAIDs must consider the effects of MS. Although they do not produce CysLTs, neutrophils do possess receptors for LTC4 and LTD4, the activation of which triggers relatively modest pro-inflammatory responses in these cells. Interference with neutrophil activation by CysLTs released from other cell types, such as monocytes and macrophages, mast cells or eosinophils, may therefore underlie the neutrophil-directed therapeutic efficacy of MS.67 In this study, we evaluated the effects of MS on the inflammatory phase of tendon healing in a rat model.

MATERIALS AND METHODS

This study was approved by local ethics committee and was conducted at the Marmara University Experimental Research and Animal Laboratory. CysLTs are potent mediators involved in various inflammatory diseases as well as lung disorders such as asthma. MS functions as a CysLT inhibitor during the inflammatory phase of tendon healing, resulting in delayed healing of an injured tendon.8 Thus, healing of an injured tendon was evaluated histologically in the inflammatory phase. Twelve 6-month old male Sprague–Dawley rats with mean weight of 220 g were included in this study. For anesthesia, the rats received 15 mg/100 g intraperitoneal (i.p.) ketamine. All the rats underwent full-thickness surgical incision of the Achilles tendon followed by primary repair. A mid longitudinal posterior 10 mm incision was made more than 4 mm proximal to the right. Achilles tendon insertion point of each rat, exposing the Achilles tendon [Figure 1a]. This nonsynovial tendon was longitudinally divided at the midportion in two halves. One half of longitudinally divided tendon was cut transversely and then sutured (synthetic absorbable suture) [Figure 1b]. The skin was also sutured (with 3-0 polyglactine) and the dressing was changed daily. No antibiotic was used for infection prophylaxis.
Figure 1

Peroperative clinical photographs showing (a) Partial tenotomy was performed before the initiating by montelukast sodium. (b) Ends of tendon was repaired with a single suture

Peroperative clinical photographs showing (a) Partial tenotomy was performed before the initiating by montelukast sodium. (b) Ends of tendon was repaired with a single suture The 12 rats were divided randomly into two groups (n = 6 each). The recommended dose of MS 10 mg/kg/day, which is that used in humans.9 MS (Singulair) was administered to the MS group at 10 mg/kg/day (1 ml/100 g animal body weight). The drug was diluted with 2.5 ml of 0.9% saline and administered (i.p.) 1 cm to the left side of the umbilicus. Rats in the control group were administered only 2.5 ml of 0.9% saline (as placebo) similarly. The first dose was administered on the first postoperative day and the dosage was continued until sacrifice. The two groups were kept in separate cages. The rats had access to standard rat chow and water ad libitum. In both groups, all six rats were sacrificed by decapitation 10 days later. The skin suture was reopened and the tendon was cut 5 mm above and 5 mm below the tendon suture site [Figure 1b]. Horizontal and longitudinal sectionsthrough the sutured region were obtained.

Histopathological analysis

The excised tendons from the rats were fixed in 10% neutral buffered formalin overnight and then dehydrated through an alcohol solution. The fixed tissues were next processed and embedded in paraffin. Sections that were 5-μ m thick were obtained using a standard rotary microtome and then were stained with hematoxylin and eosin according to standard protocols. Finally, Achilles tendons sections were examined by light microscopy (Olympus BX51, Tokyo, Japan). For the histopathological analysis, each group was evaluated for the following features; 1-inflammatory cell infiltration, 2-hemorrhage, 3-collagen fibre orientation and 4-vascularity in the inflammatory phase. Each item was graded by a single histologist without the knowledge of the specimen group according to a semi-quantitative approach as follow; absent (0), mild (1), moderate (2), moderate to severe (3) and severe (4). Statistical analysis was performed using the Chi-squared test. A P value less than 0.05 was deemed to indicate statistical significance.

RESULTS

Histopathological examination of the tissue sections revealed inflammatory cell infiltration, haemorrhage, disorganised collagen fibre orientation and increased vascularity in the control group [Figure 2a]. Decreased inflammatory cell infiltration and more properly oriented collagen fibres were observed in the MS group compared with the control group [Figure 2b]. Vascularity was also somewhat decreased in the MS group.
Figure 2

Histopathological sections showing (a) Control group. Increased vascularity (arrows), perivascular inflammatory cell infiltration (arrowhead), hemorrhage (h) and disorganised collagen fibre (*). Montelucast group. (b) Decreased inflammatory cell infiltration, more properly oriented collagen fibre (*) and somewhat decreased vascularity (arrow). (Hematoxylin and Eosin stain. ×200, original magnification)

Histopathological sections showing (a) Control group. Increased vascularity (arrows), perivascular inflammatory cell infiltration (arrowhead), hemorrhage (h) and disorganised collagen fibre (*). Montelucast group. (b) Decreased inflammatory cell infiltration, more properly oriented collagen fibre (*) and somewhat decreased vascularity (arrow). (Hematoxylin and Eosin stain. ×200, original magnification) The differences between the control and study groups regarding inflammatory cell infiltration and collagen fibre oriantation were statistically significant (P < 0.05) [Tables 1 and 2].
Table 1

Histopathological analysis of injured rat Achilles tendons in the montelukast group

Table 2

Histopathological analysis of injured rat Achilles tendons in the control group

Histopathological analysis of injured rat Achilles tendons in the montelukast group Histopathological analysis of injured rat Achilles tendons in the control group

DISCUSSION

NSAIDs have been shown to have a negative effect on tendon healing in the early proliferative phase, but could be beneficial during the remodelling phase when inflammation might impede healing.10 A significantly lower tensile strength was found in rats administered both parecoxib and indomethacin compared with the control group. Both parecoxib and indomethacin impaired tendon healing; however, the negative effect was most pronounced with parecoxib.11 Leukotriene receptor antagonists, such as MS, are currently being used to treat rhinitis and asthma; however, their anti-inflammatory role is not well understood. We investigated whether MS, a selective leukotriene antagonist, had a negative effect on tendon healing and found this to be the case. Although leukotrienes have been conventionally viewed as paracrine mediators of inflammatory disease processes, such as in asthma, more recent information suggests that they are also important participants in disease processes characterized by cellular proliferation and fibrogenesis. Indeed, MS is a potent, CysLT1 receptor antagonist that has a negative effect on tendon healing.12 In this study, we evaluated the inflammatory phase of tendon healing. In the initial inflammatory phase, which lasts about 24 h, erythrocytes, platelets and inflammatory cells, such as neutrophils, monocytes and macrophages, migrate to the wound site and eradicate necrotic materials by phagocytosis. Simultaneously, vasoactive and chemotactic factors are released that recruit tendon fibroblasts to begin collagen synthesis and deposition. Nevertheless MS has a significant and progressive inhibitory effect on collagen maturation.1314 We found decreased inflammatory cell infiltration and more properly oriented collagen fibres in the MS group compared with the control group. Vascularity was also somewhat decreased in the montelukast group. The cause of the increase in properly oriented collagen fibre was likely that inactivity markedly decreased collagen turnover. Training leads to a chronically increased collagen turnover and to some degree, depending on the type of collagen, net collagen synthesis.15 We believe that collagen fibre turnover does not depend on inflammatory situation as well as rats activity because of the remaining intact portion of the tendon. Yuan et al. found that leukotriene D4 stimulated the migration, but not the proliferation, of endothelial cells, mediated by the CysLT1 receptor and the extracellular signal-regulated kinase (ERK) pathway. This migration was inhibited by MS as a leukotriene receptor antagonist and the ERK1/2 inhibitor UO126.16 Ogasawara et al. using in situ hybridization demonstrated for the first time that mCysLT1 and mCysLT2 were expressed in subcutaneous fibroblasts.17 Tolazzi et al. in their study of 60 rats, showed that MS did not alter the contraction rate of excisional wounds but had a significant and progressively inhibitory effect on collagen maturation.14 In an investigation of collagen production, a recent in vitro study revealed that mast cells express the CysLT1 receptor, human tumour necrosis factor-α (TNF-α) production by mast cells was increased by incubation with CysLT1 and the latter increase was significantly suppressed by treatment with a selective CysLT1 receptor antagonist, MK571. Thus, because CysLT1 receptor antagonists inhibit TNF-α production by mast cells in the synovium, they may attenuate the development of collagen-induced arthritis in mice. To test this and to further examine the role of mast cells in the pathogenesis of arthritis, the therapeutic effects of a selective CysLT1 receptor antagonist (MS) were assessed in the development of collagen-induced arthritis in mice.18 Cyclic stretching of human tendon fibroblasts increases the production of PgE2 and LTB4. Blocking PgE2 production leads to increased leukotriene B (4) levels and vice versa. It was found that the use of NSAIDs may increase the levels of leukotriene B (4), thus potentially contributing to the development of tendinosis.19 Çakıcı et al.20 investigated the effects of the leukotriene receptor antagonist MS on histological, radiological and densitometric parameters of fracture healing. No significant differences was found between the two groups regarding any parameter evaluated at either time interval (P > 0.05).20 Our study possessed some limitations. Most importantly, we examined only the effects of MS during the early inflammatory phase in a nonsynovial tendon and did not assess the biomechanical impact and effect of MS on synovial tendons. To conclude, this study on rats, decreased inflammatory cell infiltration and more properly oriented collagen fibres were observed in the MS-treated group. Thus, MS decreases tendon healing by inhibiting the early inflammatory phase of the healing process. However, the long term effects of this drug on a healing need to be investigated in a biomechanical study.
  18 in total

1.  Localization and upregulation of cysteinyl leukotriene-1 receptor in asthmatic bronchial mucosa.

Authors:  Jie Zhu; Yu-Sheng Qiu; David J Figueroa; Venkata Bandi; Helen Galczenski; Kaoru Hamada; Kalpalatha K Guntupalli; Jilly F Evans; Peter K Jeffery
Journal:  Am J Respir Cell Mol Biol       Date:  2005-08-25       Impact factor: 6.914

2.  Indomethacin and celecoxib impair rotator cuff tendon-to-bone healing.

Authors:  David B Cohen; Sumito Kawamura; John R Ehteshami; Scott A Rodeo
Journal:  Am J Sports Med       Date:  2005-10-06       Impact factor: 6.202

3.  Characterization of mouse cysteinyl leukotriene receptors mCysLT1 and mCysLT2: differential pharmacological properties and tissue distribution.

Authors:  Hideaki Ogasawara; Satoshi Ishii; Takehiko Yokomizo; Takashi Kakinuma; Mayumi Komine; Kunihiko Tamaki; Takao Shimizu; Takashi Izumi
Journal:  J Biol Chem       Date:  2002-02-19       Impact factor: 5.157

4.  Leukotriene D4 stimulates the migration but not proliferation of endothelial cells mediated by the cysteinyl leukotriene cyslt(1) receptor via the extracellular signal-regulated kinase pathway.

Authors:  Yu-Mei Yuan; San-Hua Fang; Xiao-Dong Qian; Li-Ying Liu; Li-Hua Xu; Wen-Zhen Shi; Li-Hui Zhang; Yun-Bi Lu; Wei-Ping Zhang; Er-Qing Wei
Journal:  J Pharmacol Sci       Date:  2009-02       Impact factor: 3.337

5.  Negative effects of parecoxib and indomethacin on tendon healing: an experimental study in rats.

Authors:  Sigbjorn Dimmen; Lars Engebretsen; Lars Nordsletten; Jan Erik Madsen
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2009-03-19       Impact factor: 4.342

6.  Pharmacology of leukotriene receptor antagonists

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  1998-06       Impact factor: 21.405

7.  Inflammatory response of human tendon fibroblasts to cyclic mechanical stretching.

Authors:  Zhaozhu Li; Guoguang Yang; Mustafa Khan; David Stone; Savio L Y Woo; James H C Wang
Journal:  Am J Sports Med       Date:  2004-03       Impact factor: 6.202

8.  Influence of leukotriene inhibitor montelukast on wound contraction and cutaneous healing process in rats.

Authors:  Andre Ricardo D Tolazzi; Karine D Tolazzi; Mariana Garcia; Ruth M Graf; Renato S Freitas; Giorgio A P Baretta; Jorge E F Matias; Antônio C L Campos
Journal:  Aesthetic Plast Surg       Date:  2008-09-17       Impact factor: 2.326

Review 9.  Asthma treatment: antileukotriene drugs.

Authors:  P M O'Byrne
Journal:  Can Respir J       Date:  1998 Jul-Aug       Impact factor: 2.409

10.  Randomized comparison of strategies for reducing treatment in mild persistent asthma.

Authors:  Stephen P Peters; Nicholas Anthonisen; Mario Castro; Janet T Holbrook; Charles G Irvin; Lewis J Smith; Robert A Wise
Journal:  N Engl J Med       Date:  2007-05-17       Impact factor: 91.245

View more
  1 in total

1.  MOntelukast as a potential CHondroprotective treatment following Anterior cruciate ligament reconstruction (MOCHA Trial): study protocol for a double-blind, randomized, placebo-controlled clinical trial.

Authors:  Cale A Jacobs; Caitlin E W Conley; Virginia Byers Kraus; Drew A Lansdown; Brian C Lau; Xiaojuan Li; Sharmila Majumdar; Kurt P Spindler; Nicole G Lemaster; Austin V Stone
Journal:  Trials       Date:  2022-01-31       Impact factor: 2.279

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.